220 related articles for article (PubMed ID: 21878638)
21. Attenuation of drug-stimulated topoisomerase II-DNA cleavable complex formation in wild-type HL-60 cells treated with an intracellular calcium buffer is correlated with decreased cytotoxicity and site-specific hypophosphorylation of topoisomerase IIalpha.
Aoyama M; Grabowski DR; Dubyak GR; Constantinou AI; Rybicki LA; Bukowski RM; Ganapathi MK; Hickson ID; Ganapathi R
Biochem J; 1998 Dec; 336 ( Pt 3)(Pt 3):727-33. PubMed ID: 9841887
[TBL] [Abstract][Full Text] [Related]
22. Hypophosphorylation of topoisomerase IIalpha in etoposide (VP-16)-resistant human carcinoma cell lines associated with carboxy-terminal truncation.
Matsumoto Y; Takano H; Kunishio K; Nagao S; Fojo T
Jpn J Cancer Res; 2001 Jul; 92(7):799-805. PubMed ID: 11473732
[TBL] [Abstract][Full Text] [Related]
23. Predictive value of topoisomerase IIalpha and other prognostic factors for epirubicin chemotherapy in advanced breast cancer.
Järvinen TA; Holli K; Kuukasjärvi T; Isola JJ
Br J Cancer; 1998 Jun; 77(12):2267-73. PubMed ID: 9649144
[TBL] [Abstract][Full Text] [Related]
24. DNA topoisomerase IIalpha (TOP2A) inhibitors up-regulate fatty acid synthase gene expression in SK-Br3 breast cancer cells: in vitro evidence for a 'functional amplicon' involving FAS, Her-2/neu and TOP2A genes.
Menendez JA; Vellon L; Lupu R
Int J Mol Med; 2006 Dec; 18(6):1081-7. PubMed ID: 17089011
[TBL] [Abstract][Full Text] [Related]
25. A cysteine-reactive alkyl hydroquinone modifies topoisomerase IIα, enhances DNA breakage, and induces apoptosis in cancer cells.
Lin TY; Huang CP; Au LC; Chang YW; Hu CY; Lin SB
Chem Res Toxicol; 2012 Nov; 25(11):2340-51. PubMed ID: 23088786
[TBL] [Abstract][Full Text] [Related]
26. Changes in subcellular distribution of topoisomerase IIalpha correlate with etoposide resistance in multicell spheroids and xenograft tumors.
Oloumi A; MacPhail SH; Johnston PJ; Banáth JP; Olive PL
Cancer Res; 2000 Oct; 60(20):5747-53. PubMed ID: 11059769
[TBL] [Abstract][Full Text] [Related]
27. A unique paclitaxel-mediated modulation of the catalytic activity of topoisomerase IIalpha.
Dhawan V; Swaffar DS
Anticancer Drugs; 1999 Apr; 10(4):397-404. PubMed ID: 10378675
[TBL] [Abstract][Full Text] [Related]
28. Topoisomerase IIalpha controls the decatenation checkpoint.
Luo K; Yuan J; Chen J; Lou Z
Nat Cell Biol; 2009 Feb; 11(2):204-10. PubMed ID: 19098900
[TBL] [Abstract][Full Text] [Related]
29. Casein kinase I delta/epsilon phosphorylates topoisomerase IIalpha at serine-1106 and modulates DNA cleavage activity.
Grozav AG; Chikamori K; Kozuki T; Grabowski DR; Bukowski RM; Willard B; Kinter M; Andersen AH; Ganapathi R; Ganapathi MK
Nucleic Acids Res; 2009 Feb; 37(2):382-92. PubMed ID: 19043076
[TBL] [Abstract][Full Text] [Related]
30. [Topo II alpha in breast cancer: an update].
Wei J; Liu FF; Fu L
Zhonghua Bing Li Xue Za Zhi; 2008 Feb; 37(2):132-5. PubMed ID: 18681328
[No Abstract] [Full Text] [Related]
31. DNA topoisomerase IIα controls replication origin cluster licensing and firing time in Xenopus egg extracts.
Gaggioli V; Le Viet B; Germe T; Hyrien O
Nucleic Acids Res; 2013 Aug; 41(15):7313-31. PubMed ID: 23757188
[TBL] [Abstract][Full Text] [Related]
32. p38gamma mitogen-activated protein kinase integrates signaling crosstalk between Ras and estrogen receptor to increase breast cancer invasion.
Qi X; Tang J; Loesch M; Pohl N; Alkan S; Chen G
Cancer Res; 2006 Aug; 66(15):7540-7. PubMed ID: 16885352
[TBL] [Abstract][Full Text] [Related]
33. Casein kinase II stabilizes the activity of human topoisomerase IIalpha in a phosphorylation-independent manner.
Redwood C; Davies SL; Wells NJ; Fry AM; Hickson ID
J Biol Chem; 1998 Feb; 273(6):3635-42. PubMed ID: 9452492
[TBL] [Abstract][Full Text] [Related]
34. DNA topoisomerase IIalpha and -beta expression in human ovarian cancer.
Withoff S; van der Zee AG; de Jong S; Hollema H; Smit EF; Mulder NH; de Vries EG
Br J Cancer; 1999 Feb; 79(5-6):748-53. PubMed ID: 10070864
[TBL] [Abstract][Full Text] [Related]
35. UPR-induced resistance to etoposide is downstream of PERK and independent of changes in topoisomerase IIα levels.
Mann MJ; Pereira ER; Liao N; Hendershot LM
PLoS One; 2012; 7(10):e47931. PubMed ID: 23144714
[TBL] [Abstract][Full Text] [Related]
36. DNA topoisomerase II-alpha immunoreactivity as a marker of tumor aggressiveness in invasive breast cancer.
Nakopoulou L; Lazaris AC; Kavantzas N; Alexandrou P; Athanassiadou P; Keramopoulos A; Davaris P
Pathobiology; 2000; 68(3):137-43. PubMed ID: 11174071
[TBL] [Abstract][Full Text] [Related]
37. β-Elemene Inhibits Cell Proliferation by Regulating the Expression and Activity of Topoisomerases I and IIα in Human Hepatocarcinoma HepG-2 Cells.
Gong M; Liu Y; Zhang J; Gao YJ; Zhai PP; Su X; Li X; Li Y; Hou L; Cui XN
Biomed Res Int; 2015; 2015():153987. PubMed ID: 26221582
[TBL] [Abstract][Full Text] [Related]
38. The dynamics of DNA topoisomerase IIalpha in living cells.
Daum JR; Mo YY; Gorbsky GJ
Methods Mol Biol; 2009; 582():233-44. PubMed ID: 19763954
[TBL] [Abstract][Full Text] [Related]
39. Roles of the C-terminal domains of topoisomerase IIα and topoisomerase IIβ in regulation of the decatenation checkpoint.
Kozuki T; Chikamori K; Surleac MD; Micluta MA; Petrescu AJ; Norris EJ; Elson P; Hoeltge GA; Grabowski DR; Porter ACG; Ganapathi RN; Ganapathi MK
Nucleic Acids Res; 2017 Jun; 45(10):5995-6010. PubMed ID: 28472494
[TBL] [Abstract][Full Text] [Related]
40. Platinum complexes as inhibitors of DNA repair protein Ku70 and topoisomerase IIα in cancer cells.
Zhang H; Wang Y; Wang Y; Han Q; Yan H; Yang T; Guo Z; Wang X
Dalton Trans; 2022 Feb; 51(8):3188-3197. PubMed ID: 35113100
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
